Citations
Mayo Clinic
2095 citation(s) found for "Xu, Vincent".
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8).
Kaubisch, Andreas , Posey, James , Tan, Benjamin , Kavan, Petr , Goel, Rakesh, Lammers, Philip E. , Rajdev, Lakshmi , Kelley, Robin Kate , Siegel, Abby B. , Dika, Imane H. El, Abou‐Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. , Bekaii‐Saab, Tanios , Tam, Vincent C. , Zemla, Tyler , Venook, Alan P. , Bertagnolli, Monica M. , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e16107-e16107
5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.
Hamid, Omid , Hodi, F. Stephen , Hwu, Wen‐Jen , Dronca, Roxana , Mitchell, Tara C. , Patnaik, Amita , Zarour, Hassane M. , Jensen, Erin , Ibrahim, Nageatte , Ahsan, Sama, Robert, Caroline , Daud, Adil , Kefford, Richard , Wolchok, Jedd D. , Hersey, Peter , Joseph, Richard W. , Weber, Jeffrey S. , Joshua, Anthony M. , Ribas, Antoni
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 9516-9516
Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.
Voorhees, Peter M. , Goldschmidt, Hartmut , Bandekar, Rajesh, Kuppens, Steven, Qi, Ming , Rajkumar, S. Vincent , Baker, Ross , Neff, Tobias , Dimopoulos, Meletios Α.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS8062-TPS8062
Daratumumab-based therapies in patients with AL amyloidosis.
Abeykoon, Jithma P. , Zanwar, Saurabh , Kumar, Shaji , Lacy, Martha Q. , Kourelis, Taxiarchis , Kyle, Robert A. , Kapoor, Prashant , Dispenzieri, Angela , Rajkumar, S. Vincent , Dingli, David , Leung, Nelson , Muchtar, Eli , Gonsalves, Wilson I. , Buadi, Francis K. , Gertz, Morie A.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8053-8053
Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).
Tandon, Nidhi , Lacy, Martha Q. , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Sidana, Surbhi , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Dingli, David , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8045-8045
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.
Tschautscher, Marcella , Lacy, Martha Q. , Hayman, Suzanne R. , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Zeldenrust, Steven R., Lust, John A., Kapoor, Prashant , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Rajkumar, S. Vincent , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8030-8030
Predictors of disease progression in smoldering Waldenström macroglobulinemia.
Zanwar, Saurabh , Abeykoon, Jithma P. , Ansell, Stephen M. , Kumar, Shaji , Lacy, Martha Q. , Nowakowski, Grzegorz S. , Kourelis, Taxiarchis , Kyle, Robert A. , Kapoor, Prashant , Dispenzieri, Angela , Witzig, Thomas E. , Buadi, Francis K. , Dingli, David , Leung, Nelson , Rajkumar, S. Vincent , Go, Ronald S. , Habermann, Thomas M. , Lin, Yi , Gertz, Morie A.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7571-7571
A fully automatic solution for structuring prostate pathology reports.
Prinsen, Peter , Ommering, Robbert van, Janssen, Marco H.M., Loos, Marc L. M. van der, Tahmasebi, Amir , Coons, Samuel, Vincent, Per Henrik , Lindh, Claes , Akre, Olof , Rastinehad, Ardeshir R. , Mynderse, Lance A. , Rastinehad, Ardeshir R , Ommering, Rob van, Loos, Marc, Thompson, Scott, Chang, Paul J.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e18586-e18586
Toward understanding toxicity over time (ToxT) in myeloma cooperative group trials: Feasibility of a novel longitudinal adverse event analysis in ECOG-ACRIN E1A06.
Jacobus, Susanna , Novotny, Paul J. , Stewart, A. Keith, Warsame, Rahma , Midathada, Madhu, Singh, Avina A., O’Brien, Timothy E., MacFarlene, Donald, Grinblatt, David L. , Chanan‐Khan, Asher , Thanarajasingam, Gita , Callander, Natalie S. , Fonseca, Rafaël , Rajkumar, S. Vincent , Dueck, Amylou C.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 6580-6580
A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response.
Borazanci, Erkut , Jameson, Gayle , Downes, Michael , Truitt, Morgan , Patel, Hitendra , Lowy, Andrew M. , Roe, Denise J. , Ansaldo, Karen, Barrett, Michael T. , Korn, Ronald L. , Caldwell, Lana, Slethaug, Gavin, Hultsch, Rolf, Han, Haiyong , Engelthaler, David M. , Lenkiewics, Elizabeth, Hoff, Daniel D. Von , Borazanci, Erkut , Chung, Vincent , Evans, Ronald M. , Patel, Hitendra, Pearson, Talima
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS4154-TPS4154